Critical Path Institute (C-Path)
Mark Drew is an accomplished professional in drug discovery and development, currently serving as the Director of Drug Discovery & Development at the Critical Path Institute since February 2023. Previously, Mark held the position of Senior Translational Project Manager at the University of Arizona's Center for Innovation in Brain Science from September 2020 to February 2023. Mark has extensive experience as a Lead Research Investigator at Icagen and Sanofi, where responsibilities included managing discovery programs and optimizing lead compounds across multiple therapeutic areas. Mark's background also features roles as a Patent Agent and membership on the Institutional Review Board at the University of Arizona, contributing to research protocol reviews and patent evaluations. Mark holds a Ph.D. in Chemistry from The University of Manchester and an NIH Post-doctoral Research Fellowship in Organic Chemistry from Indiana University–Purdue University Indianapolis.
This person is not in the org chart
This person is not in any teams
Critical Path Institute (C-Path)
Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and dozens of pharmaceutical and biotech companies. C-Path U.S. is headquartered in Tucson, Arizona and C-Path, Ltd. EU is headquartered in Dublin, Ireland, with additional staff in multiple other locations. For more information, visit c-path.org and c-path.eu.